.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,703,772

« Back to Dashboard

Details for Patent: 8,703,772

Title:Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.
Inventor(s): Bando; Takuji (Tokushima, JP), Aoki; Satoshi (Naruto, JP), Kawasaki; Junichi (Tokushima, JP), Ishigami; Makoto (Tokushima, JP), Taniguchi; Youichi (Tokushima, JP), Yabuuchi; Tsuyoshi (Tokushima, JP), Fujimoto; Kiyoshi (Naruto, JP), Nishioka; Yoshihiro (Tokushima, JP), Kobayashi; Noriyuki (Tokushima, JP), Fujimura; Tsutomu (Naruto, JP), Takahashi; Masanori (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Nakagawa; Tomonori (Tokushima, JP), Shinhama; Koichi (Tokushima, JP), Utsumi; Naoto (Naruto, JP), Tominaga; Michiaki (Tokushima, JP), Ooi; Yoshihiro (Tokushima, JP), Yamada; Shohei (Tokushima, JP), Tomikawa; Kenji (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Filing Date:Aug 25, 2011
Application Number:13/217,636
Claims:1. Anhydrous Aripiprazole Crystals D.

2. A pharmaceutical solid oral composition comprising Anhydrous Aripiprazole Crystals D and at least one pharmaceutically acceptable carrier, wherein said pharmaceutical solid oral composition has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

3. A pharmaceutical composition comprising Anhydrous Aripiprazole Crystals D and at least one pharmaceutically acceptable carrier.

4. Anhydrous Aripiprazole Crystals D prepared by a process comprising recrystallizing aripiprazole from toluene.

5. The Anhydrous Aripiprazole Crystals D according to claim 4, wherein said aripiprazole is chosen from type-I anhydrous aripiprazole crystals, type-II anhydrous aripiprazole crystals, and mixtures thereof.

6. The Anhydrous Aripiprazole Crystals D according to claim 4, wherein said aripiprazole is chosen from Anhydrous Aripiprazole Crystals B, Anhydrous Aripiprazole Crystals C, Anhydrous Aripiprazole Crystals E, Anhydrous Aripiprazole Crystals F, Anhydrous Aripiprazole Crystals G, and mixtures thereof.

7. The Anhydrous Aripiprazole Crystals D according to claim 4, wherein said aripiprazole is Anhydrous Aripiprazole Crystals B.

8. Anhydrous aripiprazole crystals having one or more of the following properties: a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=8.7.degree., 11.6.degree., 16.3.degree., 17.7.degree., 18.6.degree., 20.3.degree., 23.4.degree., and 25.0.degree. using a Cu K.sub..alpha. x-ray; an infrared absorption spectrum comprising infrared absorption bands at 2946, 1681, 1375, 1273, 1175, and 862 cm.sup.-1 on the IR (KBr) spectrum; an endothermic curve comprising endothermic peaks at about 136.8.degree. C. and about 141.6.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min); and a solid .sup.13C-NMR spectrum comprising peaks at 32.1 ppm, 62.2 ppm, 66.6 ppm, 104.1 ppm, 152.4 ppm, 158.4 ppm, and 174.1 ppm.

9. The anhydrous aripiprazole crystals according to claim 8, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=8.7.degree., 11.6.degree., 16.3.degree., 17.7.degree., 18.6.degree., 20.3.degree., 23.4.degree., and 25.0.degree. using a Cu K.sub..alpha. x-ray.

10. The anhydrous aripiprazole crystals according to claim 8, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2946, 1681, 1375, 1273, 1175, and 862 cm.sup.-1 on the IR (KBr) spectrum.

11. The anhydrous aripiprazole crystals according to claim 8, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising endothermic peaks at about 136.8.degree. C. and about 141.6.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min).

12. The anhydrous aripiprazole crystals according to claim 8, wherein the anhydrous aripiprazole crystals have a solid .sup.13C-NMR spectrum comprising peaks at 32.1 ppm, 62.2 ppm, 66.6 ppm, 104.1 ppm, 152.4 ppm, 158.4 ppm, and 174.1 ppm.

13. Anhydrous aripiprazole crystals having one or more of the following properties: a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 15 using a Cu K.sub..alpha. x-ray; an infrared absorption spectrum which is substantially the same as the IR (KBr) spectrum shown in FIG. 16; an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 13; and a solid .sup.13C-NMR spectrum which is substantially the same as the solid .sup.13C-NMR spectrum shown in FIG. 17.

14. The anhydrous aripiprazole crystals according to claim 13, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder xray diffraction spectrum shown in FIG. 15 using a Cu K.sub..alpha. x-ray.

15. The anhydrous aripiprazole crystals according to claim 13, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum which is substantially the same as the IR (KBr) spectrum shown in FIG. 16.

16. The anhydrous aripiprazole crystals according to claim 13, wherein the anhydrous aripiprazole crystals have an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 13.

17. The anhydrous aripiprazole crystals according to claim 13, wherein the anhydrous aripiprazole crystals have a solid .sup.13C-NMR spectrum which is substantially the same as the solid .sup.13C-NMR spectrum shown in FIG. 17.

18. The anhydrous aripiprazole crystals according to any one of claim 8 or 13, wherein the anhydrous aripiprazole crystals are prepared by a process comprising recrystallizing aripiprazole from toluene.

19. The anhydrous aripiprazole crystals according to claim 18, wherein said aripiprazole is chosen from type-I anhydrous aripiprazole crystals, type-II anhydrous aripiprazole crystals, and mixtures thereof.

20. The anhydrous aripiprazole crystals according to claim 18, wherein said aripiprazole is chosen from Anhydrous Aripiprazole Crystals B, Anhydrous Aripiprazole Crystals C, Anhydrous Aripiprazole Crystals E, Anhydrous Aripiprazole Crystals F, Anhydrous Aripiprazole Crystals G, and mixtures thereof.

21. The anhydrous aripiprazole crystals according to claim 18, wherein said aripiprazole is Aripiprazole Crystals B.

22. A pharmaceutical solid oral composition comprising anhydrous aripiprazole crystals and at least one pharmaceutically acceptable carrier, wherein said pharmaceutical solid oral composition has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes; and 55% or more at pH 5.0 after 60 minutes, wherein the anhydrous aripiprazole crystals have one or more of the following properties: a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=8.7.degree., 11.6.degree., 16.3.degree., 17.7.degree., 18.6.degree., 20.3.degree., 23.4.degree., and 25.0.degree. using a Cu K.sub..alpha. x-ray; an infrared absorption spectrum comprising infrared absorption bands at 2946, 1681, 1375, 1273, 1175, and 862 cm.sup.-1 on the IR (KBr) spectrum; an endothermic curve comprising endothermic peaks at about 136.8.degree. C. and about 141.6.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min); and a solid .sup.13C-NMR spectrum comprising peaks at 32.1 ppm, 62.2 ppm, 66.6 ppm, 104.1 ppm, 152.4 ppm, 158.4 ppm, and 174.1 ppm.

23. The pharmaceutical solid oral composition according to claim 22, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=8.7.degree., 11.6.degree., 16.3.degree., 17.7.degree., 18.6.degree., 20.3.degree., 23.4.degree., and 25.0.degree. using a Cu K.sub..alpha. x-ray.

24. The pharmaceutical solid oral composition according to claim 22, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2946, 1681, 1375, 1273, 1175, and 862 cm.sup.-1 on the IR (KBr) spectrum.

25. The pharmaceutical solid oral composition according to claim 22, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising endothermic peaks at about 136.8.degree. C. and about 141.6.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min).

26. The pharmaceutical solid oral composition according to claim 22, wherein the anhydrous aripiprazole crystals have a solid .sup.13C-NMR spectrum comprising peaks at 32.1 ppm, 62.2 ppm, 66.6 ppm, 104.1 ppm, 152.4 ppm, 158.4 ppm, and 174.1 ppm.

27. A pharmaceutical solid oral composition comprising anhydrous aripiprazole crystals and at least one pharmaceutically acceptable carrier, wherein said pharmaceutical solid oral composition has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes; and 55% or more at pH 5.0 after 60 minutes, wherein the anhydrous aripiprazole crystals have one or more of the following properties: a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 15 using a Cu K.sub..alpha. x-ray; an infrared absorption spectrum which is substantially the same as the IR (KBr) spectrum shown in FIG. 16; an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 13; and a solid .sup.13C-NMR spectrum which is substantially the same as the solid .sup.13C-NMR spectrum shown in FIG. 17.

28. The pharmaceutical solid oral composition according to claim 27, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 15 using a Cu K.sub..alpha. x-ray.

29. The pharmaceutical solid oral composition according to claim 27, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum which is substantially the same as the IR (KBr) spectrum shown in FIG. 16.

30. The pharmaceutical solid oral composition according to claim 27, wherein the anhydrous aripiprazole crystals have an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 13.

31. The pharmaceutical solid oral composition according to claim 27, wherein the anhydrous aripiprazole crystals have a solid .sup.13C-NMR spectrum which is substantially the same as the solid .sup.13C-NMR spectrum shown in FIG. 17.

32. A pharmaceutical composition comprising anhydrous aripiprazole crystals and at least one pharmaceutically acceptable carrier, wherein the anhydrous aripiprazole crystals have one or more of the following properties; a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=8.7.degree., 11.6.degree., 16.3.degree., 17.7.degree., 18.6.degree., 20.3.degree., 23.4.degree., and 25.0.degree. using a Cu K.sub..alpha. x-ray; an infrared absorption spectrum comprising infrared absorption bands at 2946, 1681, 1375, 1273, 1175, and 862 cm.sup.-1 on the IR (KBr) spectrum; an endothermic curve comprising endothermic peaks at about 136.8.degree. C. and about 141.6.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min); and a solid .sup.13C-NMR spectrum comprising peaks at 32.1 ppm, 62.2 ppm, 66.6 ppm, 104.1 ppm, 152.4 ppm, 158.4 ppm, and 174.1 ppm.

33. The pharmaceutical composition according to claim 32, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=8.7.degree., 11.6.degree., 16.3.degree., 17.7.degree., 18.6.degree., 20.3.degree., 23.4.degree., and 25.0.degree. using a Cu K.sub..alpha. x-ray.

34. The pharmaceutical composition according to claim 32, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2946, 1681, 1375, 1273, 1175, and 862 cm.sup.-1 on the IR (KBr) spectrum.

35. The pharmaceutical composition according to claim 32, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising endothermic peaks at about 136.8.degree. C. and about 141.6.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min).

36. The pharmaceutical composition according to claim 32, wherein the anhydrous aripiprazole crystals have a solid .sup.13C-NMR spectrum comprising peaks at 32.1 ppm, 62.2 ppm, 66.6 ppm, 104.1 ppm, 152.4 ppm, 158.4 ppm, and 174.1 ppm.

37. A pharmaceutical composition comprising anhydrous aripiprazole crystals and at least one pharmaceutically acceptable carrier, wherein the anhydrous aripiprazole crystals have one or more of the following properties: a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 15 using a Cu K.sub..alpha. x-ray; an infrared absorption spectrum which is substantially the same as the IR (KBr) spectrum shown in FIG. 16; an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 13; and a solid .sup.13C-NMR spectrum which is substantially the same as the solid .sup.13C-NMR spectrum shown in FIG. 17.

38. The pharmaceutical composition according to claim 37, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 15 using a Cu K.sub..alpha. x-ray.

39. The pharmaceutical composition according to claim 37, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum which is substantially the same as the IR (KBr) spectrum shown in FIG. 16.

40. The pharmaceutical composition according to claim 37, wherein the anhydrous aripiprazole crystals have an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 13.

41. The pharmaceutical composition according to claim 37, wherein the anhydrous aripiprazole crystals have a solid .sup.13C-NMR spectrum which is substantially the same as the solid .sup.13C-NMR spectrum shown in FIG. 17.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc